4/A: SOPHIA GENETICS INC. - Insider Stock Transaction Update

George Cardoza, Chief Financial Officer of SOPHiA GENETICS SA, filed an amended Form 4 to correct previously reported beneficial ownership of ordinary shares.

Summary

• This filing is an amended Form 4, indicating a correction to a previous filing made on April 3, 2026.
• George Cardoza, the Chief Financial Officer of SOPHiA GENETICS SA, is the reporting person.
• The amendment corrects the amount of ordinary shares beneficially owned following a reported transaction.
• The previously reported amount was 112,936 ordinary shares, and the corrected amount is 297,794 ordinary shares.
• The transaction involves a restricted stock unit (RSU) grant and a share option.
• The RSU grant, made under the Issuer's 2021 Equity Incentive Plan, represents a contingent right to receive ordinary shares.
• The share option grants the right to buy ordinary shares at an exercise price of $5.04.
• Vesting for the RSUs begins on April 2, 2027, with 25% vesting then, and the remaining 75% vesting quarterly through April 2, 2030.
• The share option vests and becomes exercisable in stages, with 25% on April 2, 2027, and the rest monthly through April 2, 2030.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; it's an administrative correction of a previous report and does not introduce new financial information or strategic shifts.

Positives

• Correction of beneficial ownership amount to a higher figure, potentially indicating a more significant stake than initially reported.
• Grant of RSUs and share options suggests management's continued incentive and alignment with the company's long-term performance.
• Clear vesting schedules for RSUs and options provide transparency on when these securities will become fully owned and exercisable.

Negatives

• An inadvertent error in the initial filing required an amendment, which could raise minor concerns about internal reporting accuracy.

Risks

• The value of the RSUs and share options is subject to the future performance and stock price of SOPHiA GENETICS SA.
• Vesting is contingent upon the Reporting Person's continued service with the Issuer, meaning departure before vesting would result in forfeiture.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on a change in beneficial ownership due to an amendment.

Industry Context

StockSavvy.ai notes that insider filings like this Form 4/A are common for executives and directors as they are required to report changes in their holdings. While this specific filing is an amendment to correct an error, it confirms the ongoing grant and vesting of equity-based compensation, a standard practice in the biotechnology and healthcare technology sectors to attract and retain talent.

Stakeholder Impact

• Shareholders: The correction clarifies the exact beneficial ownership of the CFO, providing accurate information for assessing insider holdings. The grant of equity aligns management's interests with long-term shareholder value.

Next Steps

• Continued vesting of RSUs and share options for George Cardoza through April 2, 2030.
• Potential exercise of share options by George Cardoza after they become vested.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Options, RSU, Beneficial Ownership, SOPHiA GENETICS SA, George Cardoza, Equity Incentive Plan, Vesting Schedule